14 completed, 9 recruiting, 6 not yet recruiting, 2 active not recruiting. 19 Phase 2, 9 Phase 3, 5 Phase 1, 3 Phase 4.
Follow efgartigimod alfa: new trials by email Literature Review of efgartigimod alfa trials Research Report on efgartigimod alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC - Autoimmune Encephalitis (AE) | Phase 2 | Not yet recruiting | argenx | 170 | 2027-04-01 | 2026-09-22 |
| Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART) Efgartigimod - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Not yet recruiting | M. Peter Marinkovich | 18 | 2026-07-01 | 2026-05-05 |
| Efgartigimod in Anti-NMDA Receptor Encephalitis. Efgartigimod Alfa - Encephalitis Autoimmune | Phase 2 | Recruiting | Beijing Tongren Hospital | 20 | 2026-06-25 | 2026-09-16 |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis Nipocalimab, Efgartigimod - Myasthenia Gravis | Phase 3 | Recruiting | Janssen Research & Development, LLC | 115 | 2026-01-05 | 2026-09-25 |
| A Study of Efgartigimod in Patients With IgG4-Related Disease Efgartigimod - IgG4-related Disease | Phase 2 | Active not recruiting | Stanford University | 5 | 2025-11-12 | 2026-07-23 |
| Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod Efgartigimod - Myasthenia Gravis, Generalized | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Nice | 50 | 2025-09-19 | 2026-09-03 |
| Efgartigimod for the Treatment of Acute Optic Neuritis Efgartigimod Alfa, Placebo - Optic Neuritis | Phase 2 | Recruiting | Anastasia Vishnevetsky, MD, MPH | 20 | 2025-08-12 | 2026-10-28 |
| A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) efgartigimod - Immune-mediated Thrombotic Thrombocytopenic Purpura | Phase 2 | Recruiting | University of Minnesota | 15 | 2025-05-01 | 2026-06-11 |
| Efgartigimod for the Treatment of Guillain-Barré Syndrome efgartigimod - Guillain-Barre Syndrome (GBS) | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 20 | 2025-04-13 | 2025-03-20 |
| Efgartigimod for Stiff Person Syndrome (ESPS) Efgartigimod - Stiff-Person Syndrome | Phase 2 | Not yet recruiting | University of South Florida | 10 | 2025-04-01 | 2025-04-11 |
| Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod Efgartigimod - Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations | Phase 4 | Recruiting | University of Colorado, Denver | 20 | 2025-03-06 | 2025-07-11 |
| Efgartigimod in IVIG Dependent Myasthenia Gravis Patients efgartigimod administration - Myasthaenia Gravis | Phase 3 | Recruiting | Clinique Neuro-Outaouais | 30 | 2025-02-06 | 2026-10-22 |
| Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis IV efgartigimod - Myasthenia Gravis Crisis | Phase 4 | Not yet recruiting | Rambam Health Care Campus | 16 | 2024-11-15 | 2024-11-14 |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa efgartigimod - Myasthenia Gravis | Recruiting | argenx | 680 | 2024-11-04 | 2026-02-17 | |
| Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg) - Guillain-Barre Syndrome | Phase 2 | Withdrawn | Chafic Karam | 2024-09-10 | 2026-03-12 | |
| FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 | Unknown | Tianjin Medical University General Hospital | 63 | 2024-07-05 | 2024-07-11 |
| Perioperative Efgartigimod for Thymoma and Myasthenia Gravis Efgartigimod Alfa - Myasthenia Gravis | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2024-02-01 | 2024-01-24 |
| A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding. Efgartigimod - Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | argenx | 279 | 2023-11-30 | 2026-02-17 | |
| Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome Efgartigimod - Primary Sjögren's Syndrome | Phase 2 | Completed | argenx | 24 | 2023-11-29 | 2026-02-20 |
| Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS Efgartigimod - Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | Phase 2 | Terminated | argenx | 33 | 2023-06-20 | 2025-10-23 |
Showing 20 of 36. Sign in to see all of them.
Myasthenia Gravis (10) · Purpura, Thrombocytopenic, Idiopathic (4) · Autoimmune Diseases of the Nervous System (2) · Guillain-Barre Syndrome (2) · Neuromyelitis Optica (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Anti-N-Methyl-D-Aspartate Receptor Encephalitis (1) · Epidermolysis Bullosa (1) · Epidermolysis Bullosa Acquisita (1) · Epidermolysis Bullosa Dystrophica (1) · Immunoglobulin G4-Related Disease (1) · Multiple Sclerosis (1) · Optic Neuritis (1) · Pemphigus (1) · Post-Acute COVID-19 Syndrome (1)
argenx (20) · Anastasia Vishnevetsky, MD, MPH (1) · Beijing Tongren Hospital (1) · Centre Hospitalier Universitaire de Nice (1) · Chafic Karam (1) · Clinique Neuro-Outaouais (1) · Janssen Research & Development, LLC (1) · M. Peter Marinkovich (1) · Rambam Health Care Campus (1) · Shanghai Zhongshan Hospital (1) · Stanford University (1) · Tianjin Medical University General Hospital (1) · University Health Network, Toronto (1) · University of Colorado, Denver (1) · University of Minnesota (1)
United States (19) · Belgium (10) · Netherlands (10) · Germany (9) · Italy (9) · Poland (9) · Hungary (8) · France (7) · Spain (7) · Czechia (6) · Austria (5) · Canada (5) · Georgia (5) · Japan (5) · Russia (5)
Antonio Guglietta, MD (3) · Adrian Newland (1) · Anastasia Vishnevetsky, MD, MPH (1) · Chafic Karam, MD (1) · Colin Quinn, MD (1) · Marshall Mazepa, MD (1) · Matt P Marinkovich, MD (1) · Matthew C Baker, MD, MS (1) · Patrick Dupuy, MD (1) · Sabine Coppieters, MD (1) · Thierry Cousin, MD (1) · Thomas Ragole, MD (1) · Tuan H Vu, MD (1)
PMID 34146511, PMID 39636455, PMID 30040076, PMID 31821591, PMID 34608631, PMID 35663943, PMID 37778358, PMID 38318236, PMID 39068745, PMID 40320172, PMID 41180124, PMID 41517964, PMID 41997805, PMID 42183242, PMID 42234197, PMID 42551446
2019 (4), 2016 (2), 2018 (2), 2017 (1), 2025 (1)